The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 356:800-808 February 22, 2007 Number 8
NextNext

DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
Zhong Zheng, M.D., Ph.D., Tingan Chen, M.D., Ph.D., Xueli Li, M.D., Eric Haura, M.D., Anupama Sharma, M.D., and Gerold Bepler, M.D., Ph.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set
-Supplementary Material

Commentary
-Perspective
 by Gazdar, A. F.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background RRM1, the regulatory subunit of ribonucleotide reductase, is involved in carcinogenesis, tumor progression, and the response of non–small-cell lung cancer to treatment.

Methods We developed an automated quantitative determination of the RRM1 protein in routinely processed histologic specimens. In these specimens, we measured the expression of RRM1 and two other proteins that are relevant to non–small-cell lung cancer: the excision repair cross-complementation group 1 (ERCC1) protein and the phosphatase and tensin homologue (PTEN). We compared the results with the clinical outcomes in 187 patients with early-stage non–small-cell lung cancer who had received only surgical treatment.

Results RRM1 expression correlated with the expression of ERCC1 (P<0.001) but not with the expression of PTEN (P=0.37). The median disease-free survival exceeded 120 months in the group of patients with tumors that had high expression of RRM1 and was 54.5 months in the group with low expression of RRM1 (hazard ratio for disease progression or death in the high-expression group, 0.46; P=0.004). The overall survival was more than 120 months for patients with tumors with high expression of RRM1 and 60.2 months for those with low expression of RRM1 (hazard ratio for death, 0.61; P=0.02). Among these 187 patients, the survival advantage was limited to the 30% of patients with tumors that had a high expression of both RRM1 and ERCC1.

Conclusions RRM1 and ERCC1 are determinants of survival after surgical treatment of early-stage, non–small-cell lung cancer.


Source Information

From the Division of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Address reprint requests to Dr. Bepler at the H. Lee Moffitt Cancer Center and Research Institute, MRC-4W, Rm. 4046, 12902 Magnolia Dr., Tampa, FL 33612-9497, or at beplerg{at}moffitt.usf.edu.

Full Text of this Article


Related Letters:

ERCC1 and Non–Small-Cell Lung Cancer
Niedernhofer L. J., Bhagwat N., Wood R. D., Zhou S.-F., Panasci L., Cohen V., Bepler G., Zheng Z., Chen T.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:2538-2541, Jun 14, 2007. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.